Journal article
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
TC El-Galaly, CY Cheah, MD Bendtsen, GS Nowakowski, R Kansara, KJ Savage, JM Connors, LH Sehn, N Goldschmidt, A Shaulov, U Farooq, BK Link, AJM Ferreri, T Calimeri, C Cecchetti, EJ Dann, CA Thompson, T Inbar, MJ Maurer, IL Gade Show all
European Journal of Cancer | Published : 2018
Abstract
Purpose: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited. Methods: Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records. Results: In total, 291 patients with SCNS were included. SCNS occurred as part of first relapse in 254 (87%) patients and 113 (39%) had concurrent systemic relapse. With a median post-SCNS follow-up of..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This study received funding from the A.P. Moller og hustru Chastine Mc-Kinney Mollers Fond til almene formal (TCEG); MJM, BKL and UF was supported in part by grant P50CA97274; BKL was supported by grant U01 CA195568.